About 500 reports

SUPPLIER POWER - LOW ##.

  • Diabetes
  • North America
  • World
  • Market Size
  • CVS Caremark Corporation
  • U.K PHARMACEUTICAL PACKAGING EQUIPMENT MARKET

SUPPLIER POWER - LOW ##.

  • Diabetes
  • North America
  • World
  • Market Size
  • IMA S.p.A.
  • 8.2.1 GERMANY
  • 8.4.1 GCC

ONE SUCH PAPER IS THE ANNA HEINTZ ET AL.

  • Diabetes
  • United States
  • DuPont
  • Enterome Bioscience SA
  • Synlogic, Inc.
  • DIABETES DRUGS MARKET, GLOBAL, OVERALL PHARMACEUTICAL INDUSTRY PIPELINE
  • Pipeline Landscape Assessment

GLP-## agonists have been associated with a common side effect of gastrointestinal disturbances such as nausea and vomiting, which can reduce patient compliance (Prasad-Reddy and Isaacs, 2015).

  • Diabetes
  • World
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Eli Lilly & Co.

The company' s products mainly deal in segments such as respiratory, inflammation and autoimmunity, cardiovascular and metabolic disease (CVMD), oncology, infection, neuroscience, and gastrointestinal.

  • Diabetes
  • AstraZeneca PLC
  • Gilead Sciences, Inc.
  • Novartis AG
  • Pfizer Inc.

MARKET ##.

  • Diabetes
  • APAC
  • Europe
  • World
  • Company Sales
  • Causes of gastroparesis

These muscles contract to break up the food and lead to its movement through the gastrointestinal tract.

  • Diabetes
  • Forecast
  • Cadila Healthcare Ltd
  • GlaxoSmithKline plc
  • Valeant Pharmaceuticals International, Inc.
  • CLASSIFICATION OF DIABETIC NEUROPATHIES

IT ENROLLED ## PATIENTS, SPLIT INTO SEVEN ARMS, RECEIVING MIROGABALIN ##MG/ DAY, ##MG/ DAY, ##MG/ DAY, ##MG/ DAY, ##MG/ DAY, PREGABALIN ##MG/ DAY, OR PLACEBO, SPLIT IN A ##:##:##:##:##:##:## RATIO.

  • Diabetes
  • Forecast
  • Daiichi Sankyo Company
  • Depomed, Inc.
  • Pfizer Inc.

MARKET ##.

  • Diabetes
  • APAC
  • World
  • Company Sales
  • Market Segment

Global Blood Flow Measurement Device Market 2017-2025 ##.

  • Chronic Disease
  • Diabetes
  • Pathology
  • World
  • Forecast

Major one includes Vinyl, Nitrile, Latex etc.

  • Diabetes
  • World
  • Market Size
  • Ansell Limited
  • Top Glove Corporation Bhd

COMPETITIVE RIVALRY (HIGH) ##.

  • Diabetes
  • World
  • Market Size
  • Amway Corporation
  • DuPont

BRAIN STROKE The blood flow disturbance in the gastrointestinal tract can lead to serious illness such as arterial or venous occlusion or hypotonia, peptic ulcer, and gastrointestinal tract ischemia, which may lead to extensive necrosis of the intestine.

  • Diabetes
  • World
  • GE Healthcare Limited
  • Koninklijke Philips N.V.
  • Medtronic, Inc.
  • MARKET ANALYSIS 2016

Oral GLP-## capsule is based on the company' s POD technology (protein oral technology to protect orally delivered proteins from harmful enzymatic activity in the gastrointestinal tract and to enhance absorption across the intestinal wall). , and could significantly enhance comp

  • Diabetes
  • Eli Lilly & Co.
  • Merck & Co., Inc.
  • Novo Nordisk Group
  • Sanofi S.A.

Top ## players hold majority of stake in the market ##.

  • Diabetes
  • World
  • Market Size
  • Baxter International Inc.
  • Gilead Sciences, Inc.

By the year 2040, ## adult in ## will have diabetes.

  • Diabetes
  • Insulin Delivery
  • World
  • Market Size
  • Animas Corporation
  • Conclusion

GLP-## IS AN INCRETIN HORMONE THAT IS RELEASED FROM CELLS IN THE GASTROINTESTINAL TRACT INTO THE CIRCULATION IN RESPONSE TO INGESTED NUTRIENTS FROM FOOD.

  • Diabetes
  • Southeast Asia
  • Market Size
  • Novo Nordisk Group
  • Sanofi S.A.

It is growing by ##%-##% year on year.

  • Diabetes
  • Epidemiology
  • World
  • Forecast
  • Market Segment

It is growing by ##%-##% year on year.

  • Diabetes
  • Epidemiology
  • World
  • Forecast
  • Market Segment
  • ASTRAZENECA

These agents are associated with reduced rates of hypoglycemia, moderate and continuous weight loss, and gastrointestinal side effects such as nausea and vomiting.

  • Diabetes
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.
  • ORAL PROTEINS / PEPTIDES MARKET: POTENTIAL CANDIDATES
  • ORAL PROTEINS / PEPTIDES: DISTRIBUTION BY THERAPEUTIC AREA

DIGESTIVE AND GASTROINTESTINAL DISORDERS DIGESTIVE AND GASTROINTESTINAL DISORDERS ARE ONE OF THERAPEUTIC AREAS THAT ARE TARGETED BY SEVERAL ORAL PEPTIDE / PROTEIN THERAPEUTICS THAT ARE EITHER MARKETED OR UNDER DEVELOPMENT.

  • Diabetes
  • North America
  • United States
  • Ironwood Pharmaceuticals, Inc.
  • Novo Nordisk Group
  • 7.1 OVERVIEW

DESPITE ITS LOW COST, GASTROINTESTINAL (GI) SIDE EFFECTS ARE VERY COMMON WITH ACARBOSE, WHICH HAS PREVENTED ITS WIDESPREAD USE.

  • Diabetes
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.
  • Nu clear receptor, 1, 3%
  • DIABETES AND OBESITY THERAPEUTICS MARKET, GLOBAL, REVENUE FORECAST FOR ERTUGLIFLOZIN

One-year treatment of obesity: a randomized, double-blind, placebocontrolled, multicenter study of orlistat, a gastrointestinal lipase inhibitor.

  • Diabetes
  • World
  • Eli Lilly & Co.
  • Merck & Co., Inc.
  • Novo Nordisk Group
  • ROCHE/GENENTECH, ME PORTFOLIO ASSESSMENT, 2017

Seminars in Diabetologica; ##(##): ##-##.

  • Diabetes
  • Allergan plc
  • Clearside Biomedical, Inc.
  • Novartis AG
  • Regeneron Pharmaceuticals, Inc.
  • Market Landscape

Also, the people in the age group ##−## years, ## in ## men and ## in ## women suffer from CKD across the world.

  • Diabetes
  • World
  • Actavis plc
  • AMAG Pharmaceuticals, Inc.
  • Vifor Pharma
  • Revenue Breakdown (%), by Operating Segment, 2017

GLUCOSE MONITORING DEVICES MARKET (2018-2023) Report ##.

  • Diabetes
  • United States
  • World
  • DexCom, Inc.
  • Medtronic, Inc.
  • Pipeline analysis

Sotagliflozin is a small molecule and exhibits its mechanism by inhibiting SGLT-##, which helps absorb glucose and galactose in the gastrointestinal (GI) tract, and SGLT-##, which helps in glucose reabsorption by the kidney.

  • Diabetes
  • World
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.

GASTROINTESTINAL ADVERSE EFFECTS WERE MORE COMMON IN THE VICTOZA TREATMENT ARM COMPARED TO BYDUREON.

  • Diabetes
  • United States
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Takeda Pharmaceutical Company Limited

Oramed' s oral glucagon-like peptide-## (GLP-##) capsule is based on the company' s POD technology (protein oral technology to protect orally delivered proteins from harmful enzymatic activity in the gastrointestinal tract and to enhance absorption across the intesti

  • Diabetes
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Oramed Pharmaceuticals Inc.
  • Sanofi S.A.
  • MARKET SIZE AND FORECAST 2017-2022

GLP-## receptor agonists can be classified into short-acting and long-acting GLP-## receptor agonists.

  • Diabetes
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • Merck & Co., Inc.
  • Sanofi S.A.